Two breast cancer treatment drugs to be discussed at conference
Sep 20, 2011
Doctors and investors will be meeting this Friday to determine the importance of two drugs that were recently developed, according to Reuters.
Roche and Novartis, which are Swiss drug creators that developed the two new drugs, will be discussing T-DM1 and Afinitor at the annual EMCC European Cancer Congress. They will also be presenting the possibility of combining both drugs for breast cancer treatment.
Afinitor is aimed at women who have not responded to certain hormonal treatment, whereas T-DM1 is a replacement to chemotherapy, as it does not have the same side effects.
"The breast cancer story is a very nice journey for everolimus," Alessandro Riva, global head of oncology development and medical affairs at Novartis, told the news source. "The journey is not finished because we have a large program now ongoing in the HER2-positive metastatic breast cancer patients."
According to American Cancer Society, one in eight women in the U.S. will eventually be diagnosed with breast cancer at some point during their lifetime. Even though it is the second leading cause of cancer-related death, the fatality rate has been diminishing since 1990 due to advancements in research.